Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt

• Status: Completed
• Trial end date: 2020-12-12
• Target enrollment: 0
• Participant gender: All

Summary

Sofosbuvir has been recently recommended as a possible antiviral for COVID-19, based on structural studies and multiple alignment analysis. By comparing the positive-stranded RNA genomes of HCV and SARS-CoV-2, it has been postulated that sofosbuvir might be an optimal nucleotide analogue to repurpose for COVID-19 treatment

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alexandria University
• Treatments: Sofosbuvir

Criteria

Inclusion Criteria:

• mild- moderate COVID-19 confirmed by PCR

Exclusion Criteria:

1. Patients on renal dialysis

2. Severe COVID-19 cases

3. Patients on amiodarone therapy (given the reported FDA warning of an interaction between amiodarone and sofosbuvir that might lead to severe bradycardia).

4. Children < 12 years

5. Pregnant and breast feeding women

6. Exacerbation of hepatitis B